Implantica Beheer

Beheer criteriumcontroles 3/4

De CEO Implantica is Peter Forsell, benoemd in Jan2015, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt € 204.27K, bestaande uit 99.8% salaris en 0.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 87.11% van de aandelen van het bedrijf, ter waarde € 772.50M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4.8 jaar.

Belangrijke informatie

Peter Forsell

Algemeen directeur

€204.3k

Totale compensatie

Percentage CEO-salaris	99.8%
Dienstverband CEO	9.8yrs
Eigendom CEO	87.1%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Peter Forsell's beloning veranderd ten opzichte van Implantica's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-€25m
Jun 30 2024	n/a	n/a	-€24m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€204k	€204k	-€24m
Sep 30 2023	n/a	n/a	-€20m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€21m
Dec 31 2022	€200k	€200k	-€21m

Compensatie versus markt: De totale vergoeding ($USD 216.16K ) Peter } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.42M ).

Compensatie versus inkomsten: De vergoeding van Peter is gestegen terwijl het bedrijf verliesgevend is.

CEO

Peter Forsell (70 yo)

9.8yrs

Tenure

€204,274

Compensatie

Dr. Peter Forsell founded Implantica AG in 2015 and serves as its Chief Executive Officer since 2015.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Forsell	Founder & CEO	9.8yrs	€204.27k	87.11% € 772.5m
Andreas Öhrnberg	Chief Financial Officer	4.8yrs	geen gegevens	0.0084% € 74.8k
Stephan Siegenthaler	Chief Strategy Officer & Board Member	no data	geen gegevens	0.32% € 2.8m
Nicole Pehrsson	Chief Corporate Affairs Officer	2.4yrs	geen gegevens	0.17% € 1.5m
Amit Kukreja	Chief Market Access & Strategy Officer	3.8yrs	geen gegevens	geen gegevens
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 8IM1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephan Siegenthaler	Chief Strategy Officer & Board Member	4.8yrs	geen gegevens	0.32% € 2.8m
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	geen gegevens	geen gegevens
Liselott Kilaas	Independent Chair of the Board	4.8yrs	€36.02k	0.0099% € 88.1k
Tomas Puusepp	Independent Board Member	4.3yrs	€50.43k	0.0071% € 62.6k
Felix Zulauf	Member of Advisory Board	no data	geen gegevens	geen gegevens
Johan Bojs	Vice-Chairman of the Board	4.8yrs	€10.29k	0.047% € 414.6k
Piet Pattyn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Steven Wilson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kaspar Z'graggen	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8IM1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Implantica Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Chief Corporate Affairs Officer recently bought €108k worth of stock

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Recent updates

Third quarter 2024 earnings released: €0.09 loss per share (vs €0.019 loss in 3Q 2023)

Implantica AG to Report Q4, 2024 Results on Feb 14, 2025

Implantica AG (publ.) Submits FDA PMA Application Clinical Module 2 for RefluxStop for U.S. Market Approval

Implantica AG to Report Q3, 2024 Results on Nov 15, 2024

Implantica Ag (Publ.) Announces Highly Successful 2024 American Foregut Society Meeting Where Refluxstop Received Remarkable Pre- Launch Market Feedback

Implantica AG announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop

Implantica AG Announces Excellent Data from an Independent Study of 158 RefluxStop Patients from Two Centers in Germany - Presented at the AUGIS Meeting in UK

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Second quarter 2024 earnings released: €0.09 loss per share (vs €0.018 loss in 2Q 2023)

Implantica AG Announces Refluxstop Pivotal 4-Year Study Results Published in the Prestigious Journal Surgical Endoscopy

Implantica Announces Continuing Progress in Modular PMA Application to FDA for Refluxstop

Implantica Announces New Health-economics Data Publication Showing RefluxStop's Superior Cost-Effectiveness for the Swiss Healthcare System

First quarter 2024 earnings released: €0.05 loss per share (vs €0.016 loss in 1Q 2023)

Implantica Submits U.S. FDA Premarket Approval (PMA) Application for RefluxStop® (first module)

Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process

Full year 2023 earnings released: €0.34 loss per share (vs €0.074 loss in FY 2022)

Implantica AG to Report Fiscal Year 2023 Results on Apr 26, 2024

Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin

Chief Corporate Affairs Officer recently bought €108k worth of stock

Third quarter 2023 earnings released: €0.019 loss per share (vs €0.02 loss in 3Q 2022)

Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK

Insufficient new directors

Implantica AG to Report Q4, 2023 Results on Feb 20, 2024

Implantica AG to Report Q2, 2023 Results on Aug 24, 2023

Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago

Implantica AG to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: €0.074 loss per share (vs €0.055 loss in FY 2021)

Full year 2022 earnings released: €0.30 loss per share (vs €0.055 loss in FY 2021)

Third quarter 2022 earnings released: €0.08 loss per share (vs €0.015 loss in 3Q 2021)

Third quarter 2022 earnings released: €0.08 loss per share (vs €0.015 loss in 3Q 2021)

High number of new and inexperienced directors

Second quarter 2022 earnings released: €0.08 loss per share (vs €0.042 loss in 2Q 2021)

First quarter 2022 earnings released: €0.07 loss per share (vs €0.03 loss in 1Q 2021)

Implantica AG to Report Q4, 2022 Results on Feb 17, 2023

Implantica AG to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Full year 2021 earnings released: €0.055 loss per share (vs €0.039 loss in FY 2020)

Implantica Ag Announces Launch of Refluxstop™ in Uk

Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Implantica AG to Report Q4, 2021 Results on Feb 18, 2022

Implantica AG Appoints Paul Meadas as Chief Operating Officer

High number of new and inexperienced directors

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vice-Chairman of the Board recently sold €1.4m worth of stock

Second quarter 2021 earnings released: €0.04 loss per share (vs €0.10 loss in 2Q 2020)

Implantica Achieves Regulatory Authorisation for RefluxStop™ in New Zealand

Implantica AG (publ) Makes Headway in Italy and Spain with Its Medical Device RefluxStop™

Implantica Advances in Sweden with its Medical Device Refluxstop™

Revenue misses expectations

Implantica AG to Report Q4, 2020 Results on Feb 25, 2021

Implantica AG (publ)'s RefluxStop™ Makes Strides in the UK

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd